BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...oncology plays that raised large IPOs last year.Kinnate Biopharma Inc....
BioCentury | Dec 4, 2020
Finance

NASDAQ IPOs near $20B raised in ‘20, as Kinnate prices deal

...just shy of $20 billion, also a record.Kinnate Biopharma Inc....
...– Fibroblast growth factor (FGF) receptor 3 Jeff Cranmer Kinnate Biopharma Inc....
BioCentury | Aug 26, 2020
Finance

Expanded management team, precision cancer therapies draw crossovers to Kinnate’s $98M series C

...company. If it does go public this year before its lead BRAF inhibitor reaches the clinic, Kinnate Biopharma Inc....
...– Fibroblast growth factor (FGF) receptor 2FGFR3 (FGFR3; CD333) – Fibroblast growth factor (FGF) receptor 3 Amanda Micklus Kinnate Biopharma Inc. Biotech financing venture oncology targeted...
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

...its succession plans for the post. Nima Farzan will become CEO of precision oncology company Kinnate Biopharma Inc....
...Inc. Seer Inc. Meridian Biopharmaceuticals Liquidia Technologies Inc. Amphista Therapeutics Ltd. Science 37 Inc. Amylyx Pharmaceutical Oligomerix Inc. Galecto Inc. Applied Therapeutics Inc. Relmada Therapeutics Inc. Kinnate Biopharma Inc. Immunomedics...
BioCentury | Dec 20, 2019
Financial News

Combining kinase biology with precision oncology, Kinnate raises $75M series B

...led Kinnate’s $22 million series A in April 2018, with participation from Eshelman. San Diego-based Kinnate Biopharma Inc....
...along with Foresite's Brett Zbar and Michael Rome. Elizabeth S. Eaton, Staff Writer Nextech Invest OrbiMed Advisors Vida Ventures Foresite Capital Kinnate Biopharma Inc. kinase...
Items per page:
1 - 5 of 5
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...oncology plays that raised large IPOs last year.Kinnate Biopharma Inc....
BioCentury | Dec 4, 2020
Finance

NASDAQ IPOs near $20B raised in ‘20, as Kinnate prices deal

...just shy of $20 billion, also a record.Kinnate Biopharma Inc....
...– Fibroblast growth factor (FGF) receptor 3 Jeff Cranmer Kinnate Biopharma Inc....
BioCentury | Aug 26, 2020
Finance

Expanded management team, precision cancer therapies draw crossovers to Kinnate’s $98M series C

...company. If it does go public this year before its lead BRAF inhibitor reaches the clinic, Kinnate Biopharma Inc....
...– Fibroblast growth factor (FGF) receptor 2FGFR3 (FGFR3; CD333) – Fibroblast growth factor (FGF) receptor 3 Amanda Micklus Kinnate Biopharma Inc. Biotech financing venture oncology targeted...
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

...its succession plans for the post. Nima Farzan will become CEO of precision oncology company Kinnate Biopharma Inc....
...Inc. Seer Inc. Meridian Biopharmaceuticals Liquidia Technologies Inc. Amphista Therapeutics Ltd. Science 37 Inc. Amylyx Pharmaceutical Oligomerix Inc. Galecto Inc. Applied Therapeutics Inc. Relmada Therapeutics Inc. Kinnate Biopharma Inc. Immunomedics...
BioCentury | Dec 20, 2019
Financial News

Combining kinase biology with precision oncology, Kinnate raises $75M series B

...led Kinnate’s $22 million series A in April 2018, with participation from Eshelman. San Diego-based Kinnate Biopharma Inc....
...along with Foresite's Brett Zbar and Michael Rome. Elizabeth S. Eaton, Staff Writer Nextech Invest OrbiMed Advisors Vida Ventures Foresite Capital Kinnate Biopharma Inc. kinase...
Items per page:
1 - 5 of 5